Login to Your Account



Potential Value: $1B

Miragen, Servier Ink $352M Preclinical Micro-RNA Deal

By Jennifer Boggs


Wednesday, October 19, 2011
Miragen Therapeutics Inc.'s preclinical micro-RNA program for cardiovascular disease captured the attention of French pharma Les Laboratoires Servier, which agreed to license rights to two lead compounds and jointly develop a third in a deal that's valued at up to $352 million but could end up being worth much more to the small biotech.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription